Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364390 | 0.92 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5367185 | 0.90 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17102370 | 0.87 | SMN1; SMN2 (0.41) | ALDH1A1MAPTHPGDTSHRNPSR1 | |
| SCHEMBL32677308 | 0.87 | SMN1; SMN2 (0.41) | ALDH1A1MAPTHPGDTSHRNPSR1 | |
| SCHEMBL5369933 | 0.87 | MTNR1A (0.54) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL6997653 | 0.86 | MTNR1A (0.49) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5361550 | 0.85 | MTNR1A (0.67) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL18661751 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5368738 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 | |
| SCHEMBL5367094 | 0.84 | MTNR1A (0.55) | MTNR1AMTNR1BKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2017-03-23 | — | — | US | claimed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | claimed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | claimed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | claimed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | claimed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | claimed |
| US-10676747-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2020-06-09 | — | — | US | disclosed |
| US-10676747-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2020-06-09 | — | — | US | disclosed |
| US-20190119684-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2019-04-25 | — | — | US | disclosed |
| US-20190119684-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2019-04-25 | — | — | US | disclosed |
| US-10113171-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2018-10-30 | — | — | US | disclosed |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| US-7235550-B2 | Polycyclic azaindole compounds | LES LABORATOIRES SERVIER (FR) | 2007-06-26 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676747-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, POLRMT | MTNR1A 309/4885MTNR1B 494/4885KDM4E 3206/4885 |
| US-10113171-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, DHFR | MTNR1A 401/4885MTNR1B 547/4885KDM4E 3241/4885 |
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | MTNR1A 450/4885MTNR1B 520/4885KDM4E 1873/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | MTNR1A 1/4885MTNR1B 2/4885KDM4E 2583/4885 |
| US-20190119684-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | GSTA2, NQO1, POLRMT | MTNR1A 309/4885MTNR1B 494/4885KDM4E 3206/4885 |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, DHFR | MTNR1A 401/4885MTNR1B 547/4885KDM4E 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.